ARTICLEhttps://harbor.dev.pubfactory.com/view/journals/jnccn/8/Suppl_1/article-pS-13.xmlComplications of Multiple Myeloma Therapy, Part 2: Risk Reduction and Management of Venous Thromboembolism, Osteonecrosis of the Jaw, Renal Complications, and Anemia2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/8/Suppl_1/article-pS-13.pdf2026-04-18Complications of Multiple Myeloma Therapy, Part 2: Risk Reduction and Management of Venous Thromboembolism, Osteonecrosis of the Jaw, Renal Complications, and Anemiahttps://harbor.dev.pubfactory.com/view/journals/jnccn/8/Suppl_1/article-pS-21.xmlThe Role of Maintenance Therapy in the Treatment of Multiple Myeloma2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/8/Suppl_1/article-pS-21.pdf2026-04-18The Role of Maintenance Therapy in the Treatment of Multiple Myelomahttps://harbor.dev.pubfactory.com/view/journals/jnccn/8/Suppl_1/article-pS-1.xmlIntroduction: Addressing Challenges in Multiple Myeloma Management in an Era of New Therapeutics2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/8/Suppl_1/article-pS-1.pdf2026-04-18Introduction: Addressing Challenges in Multiple Myeloma Management in an Era of New Therapeuticshttps://harbor.dev.pubfactory.com/view/journals/jnccn/8/Suppl_1/article-pS-28.xmlIn the Age of Novel Therapies, What Defines High-Risk Multiple Myeloma?2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/8/Suppl_1/article-pS-28.pdf2026-04-18In the Age of Novel Therapies, What Defines High-Risk Multiple Myeloma?https://harbor.dev.pubfactory.com/view/journals/jnccn/8/2/article-p162.xmlProstate Cancer2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/8/2/article-p162.pdf2026-04-18Prostate Cancerhttps://harbor.dev.pubfactory.com/view/journals/jnccn/8/2/article-p148.xmlA Method for Using Life Tables to Estimate Lifetime Risk for Prostate Cancer Death2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/8/2/article-p148.pdf2026-04-18A Method for Using Life Tables to Estimate Lifetime Risk for Prostate Cancer Deathhttps://harbor.dev.pubfactory.com/view/journals/jnccn/8/2/article-p145.xmlThe 2010 NCCN Clinical Practice Guidelines in Oncology on Prostate Cancer2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/8/2/article-p145.pdf2026-04-18The 2010 NCCN Clinical Practice Guidelines in Oncology on Prostate Cancerhttps://harbor.dev.pubfactory.com/view/journals/jnccn/8/2/article-p211.xmlAdverse Effects of Androgen Deprivation Therapy: Defining the Problem and Promoting Health Among Men with Prostate Cancer2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/8/2/article-p211.pdf2026-04-18Adverse Effects of Androgen Deprivation Therapy: Defining the Problem and Promoting Health Among Men with Prostate Cancerhttps://harbor.dev.pubfactory.com/view/journals/jnccn/8/2/article-p201.xmlAppropriate Use of Nomograms to Guide Prostate Cancer Treatment Selection2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/8/2/article-p201.pdf2026-04-18Appropriate Use of Nomograms to Guide Prostate Cancer Treatment Selectionhttps://harbor.dev.pubfactory.com/view/journals/jnccn/8/2/article-p240.xmlProstate Cancer Early Detection2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/8/2/article-p240.pdf2026-04-18Prostate Cancer Early Detectionhttps://harbor.dev.pubfactory.com/view/journals/jnccn/8/2/article-p271.xmlUse of Nomograms for Early Detection in Prostate Cancer2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/8/2/article-p271.pdf2026-04-18Use of Nomograms for Early Detection in Prostate Cancerhttps://harbor.dev.pubfactory.com/view/journals/jnccn/8/2/article-p228.xmlSalvage or Adjuvant Radiation Therapy: Counseling Patients on the Benefits2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/8/2/article-p228.pdf2026-04-18Salvage or Adjuvant Radiation Therapy: Counseling Patients on the Benefitshttps://harbor.dev.pubfactory.com/view/journals/jnccn/8/2/article-p265.xmlProstate Cancer Screening and Determining the Appropriate Prostate-Specific Antigen Cutoff Values2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/8/2/article-p265.pdf2026-04-18Prostate Cancer Screening and Determining the Appropriate Prostate-Specific Antigen Cutoff Valueshttps://harbor.dev.pubfactory.com/view/journals/jnccn/8/Suppl_1/article-pS-4.xmlComplications of Multiple Myeloma Therapy, Part 1: Risk Reduction and Management of Peripheral Neuropathy and Asthenia2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/8/Suppl_1/article-pS-4.pdf2026-04-18Complications of Multiple Myeloma Therapy, Part 1: Risk Reduction and Management of Peripheral Neuropathy and Asthenia